HIV/AIDS Treatments

Find HIV/AIDS Treatments

Human Immunodeficiency Virus (HIV) and its advanced stage, Acquired Immunodeficiency Syndrome (AIDS), represent a serious diagnosis, but modern medicine has transformed this condition from a fatal illness into a chronic, manageable health challenge. For those living with HIV, treatment offers hope, health, and a near-normal life expectancy. However, receiving the diagnosis can still bring emotional weight and concern about the future.

Treatment is essential for two critical reasons: to suppress the virus within the body and to preserve the immune system. By lowering the amount of HIV in the blood to an undetectable level, the medication protects the body’s CD4+ T-cells, which are vital for fighting off infections. Furthermore, when the virus is undetectable, it cannot be transmitted to sexual partners, a concept known as Undetectable = Untransmittable (U=U) (Centers for Disease Control and Prevention, 2023). Treatment must be started promptly and tailored to the specific strain of the virus and the patient’s overall health profile.

Overview of treatment options for HIV/AIDS

The sole treatment strategy for HIV is Antiretroviral Therapy (ART). ART is not a single drug but a combination of medications designed to attack the virus at multiple points in its life cycle. Current guidelines recommend that all individuals diagnosed with HIV begin ART as soon as possible, regardless of their CD4 count or clinical stage.

The main goal of ART is to achieve and maintain an undetectable viral load, meaning the amount of HIV in the blood is too low to be measured by standard tests. Treatment is lifelong and requires extremely high adherence to be successful. Medication is always prioritized over other interventions, though vaccinations and lifestyle choices (like not smoking) remain critical for maintaining a robust immune system.

Medications used for HIV/AIDS

A typical ART regimen consists of two or three drugs from at least two different drug classes. These classes target specific enzymes or processes the virus needs to replicate:

  1. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs): These form the backbone of most regimens. Common examples include tenofovir and emtricitabine.
  2. Integrase Strand Transfer Inhibitors (INSTIs): This is one of the most potent and best-tolerated classes. Examples include dolutegravir and bictegravir. INSTIs are often combined with NRTIs in single, easy-to-take daily pills.
  3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): This class is often used as an alternative option, with examples such as efavirenz.
  4. Protease Inhibitors (PIs): PIs like atazanavir or darunavir prevent the virus from assembling new particles. They are often given with a “booster” (like ritonavir or cobicistat) to enhance their effectiveness.

Clinical studies demonstrate that modern triple-drug regimens can suppress the virus and normalize the CD4 cell count, allowing individuals living with HIV to enjoy long, healthy lives (National Institutes of Health, 2024).

How these medications work

HIV is a retrovirus, meaning it must convert its genetic material (RNA) into DNA to insert itself into the host’s immune cell (T-cell). Antiretroviral drugs interrupt this process at key stages:

  • NRTIs and NNRTIs: These inhibitors block the enzyme reverse transcriptase, which the virus uses to convert its RNA into DNA. The drugs act as faulty building blocks, stopping the conversion process and halting replication.
  • INSTIs: These prevent the enzyme integrase from inserting the viral DNA into the host cell’s DNA, effectively stopping the takeover of the T-cell’s machinery.
  • PIs: These block the enzyme protease, which is needed late in the viral lifecycle to cut large viral proteins into smaller pieces to build new, mature viruses. PIs stop the assembly line, ensuring the newly formed viral particles are non-infectious.

By combining drugs that target different stages, doctors ensure the virus is suppressed, which also prevents it from developing resistance to any one drug.

Side effects and safety considerations

While modern ART regimens have vastly improved tolerance, side effects remain possible, especially when starting treatment. Mild, temporary side effects (nausea, diarrhea, headache, fatigue) often improve early on.

While older drugs caused long-term issues like kidney problems or low bone density, modern therapy requires routine monitoring (blood pressure, kidney function) for safety. Never stop or interrupt ART without a provider’s consultation; doing so risks rapid viral multiplication and drug resistance. Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. Centers for Disease Control and Prevention. https://www.cdc.gov
  2. National Institutes of Health. https://www.nih.gov
  3. MedlinePlus. https://medlineplus.gov
  4. Mayo Clinic. https://www.mayoclinic.org

Medications for HIV/AIDS

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in HIV/AIDS.

Found 36 Approved Drugs for HIV/AIDS

Emtricitabine

Brand Names
Biktarvy, Complera, Descovy, Efavirenz, Emtriva, Genvoya, Odefsey, Stribild, Truvada

Emtricitabine

Brand Names
Biktarvy, Complera, Descovy, Efavirenz, Emtriva, Genvoya, Odefsey, Stribild, Truvada
BIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg: who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir. BIKTARVY is a three-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg: who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir. ( 1 )

Lamivudine

Brand Names
Abacavir, Cimduo, Combivir, Delstrigo, Dovato, Efavirenz, Epivir, SYMFI, Triumeq

Lamivudine

Brand Names
Abacavir, Cimduo, Combivir, Delstrigo, Dovato, Efavirenz, Epivir, SYMFI, Triumeq
Abacavir and lamivudine tablet, a combination of abacavir and lamivudine, both nucleoside analogue HIV-1 reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. ( 1 ) Abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

Darunavir

Brand Names
Darunavir 600, Prezista, Symtuza

Darunavir

Brand Names
Darunavir 600, Prezista, Symtuza
Darunavir tablets, co-administered with ritonavir (darunavir/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adult and pediatric patients 3 years of age and older [see Use in Specific Populations.

Viread

Generic Name
Tenofovir Disoproxil

Viread

Generic Name
Tenofovir Disoproxil
VIREAD is a nucleotide analog HIV-1 reverse transcriptase inhibitor and an HBV reverse transcriptase inhibitor and is indicated: in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older weighing at least 10 kg.

Ritonavir

Brand Names
Kaletra, Lopinavir, Norvir, Paxlovid

Ritonavir

Brand Names
Kaletra, Lopinavir, Norvir, Paxlovid
KALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 14 days and older. Limitations of Use: Genotypic or phenotypic testing and/or treatment history should guide the use of KALETRA. The number of baseline lopinavir resistance-associated substitutions affects the virologic response to KALETRA [see Microbiology ( 1.
Showing 1-5 of 36
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances